title: Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
abstract: The aim of this study was to compare the bioavailability of cyclosporine (CyA) from the generic dispersion formulation Cicloral (CIC) with the microemulsion formulation Neoral (NEO) and the original Sandimmune (SIM) capsules after single doses of 100, 300, or 600 mg of drug, respectively. The study was performed according to an open 3-period cross-over design with 12 young healthy male volunteers for each dosage. The concentrations of CyA and its main metabolites were determined by high performance liquid chromatography in whole blood and urine up to 48 hours postdosing. Peak concentrations and area under the time-concentration curve were greater for the NEO and CIC formulations compared with SIM, and the mean bioavailability of CIC was significantly (P<0.05) lower compared with NEO. The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results. Bioequivalence was not demonstrated between CIC (test) and NEO (reference) as the 90% confidence intervals were outside the 80% to 125% guidelines based on log-transformed AUCs, and were 75.2% to 87.7% at 100 mg, 79.2% to 91.8% at 300 mg, and 76.6% to 94.5% at 600 mg doses. The respective values for Cmax were 78.9% to 94.6%, 80.7% to 95.0%, and 71.4% to 84.1%. A good correlation was demonstrated between the urinary recovery of CyA and the AUC4. Therefore, the urinary recovery of CyA may be helpful as a surrogate parameter for the systemic exposure of patients to CyA. Whereas the relative amount of hydroxylated metabolites (AM1, AM9, AM1c) was similar for all formulations and doses, the urinary recovery of the N-demethylated metabolite AM4N decreased with increasing dose indicating saturable metabolism. No relationship could be demonstrated between CYP3A activity using dextromethorphan as a probe for the metabolic clearance of CyA.
authors.affiliation: Department of Pharmacology, University of Regensburg, Germany. Frieder.Kees@chemie.uni-regensburg.de
authors.forename: Frieder
authors.initials: F
authors.lastname: Kees
authors.forename: Michael
authors.initials: M
authors.lastname: Bucher
authors.forename: Frank
authors.initials: F
authors.lastname: Schweda
authors.forename: Harald
authors.initials: H
authors.lastname: Gschaidmeier
authors.forename: Juergen
authors.initials: J
authors.lastname: Burhenne
authors.forename: Gerd
authors.initials: G
authors.lastname: Mikus
authors.forename: Lothar
authors.initials: L
authors.lastname: Faerber
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D003915:Dextromethorphan / Q000494:pharmacology; D016568:Drugs, Generic / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004655:Emulsions; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D010641:Phenotype
chemical_list: D016568:Drugs, Generic; D004655:Emulsions; D007166:Immunosuppressive Agents; D003915:Dextromethorphan; D016572:Cyclosporine; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A